ANBL1531: A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Grant

Date/time Interval

  • March 20, 2019 - March 19, 2024
  • Total Award Amount

  • 22000.00
  • Direct Costs

  • 18333.00
  • Sponsor Award Id

  • Contributor

  • Kutny M.D., Matthew   Principal Investigator